Key result
Amiodarone exposure in a 72-year-old male resulted in severe immune thrombocytopenia with a platelet nadir of 14 K/mm3, which began recovering after drug discontinuation.
Why the study?
Thrombocytopenia is a rare immune-mediated complication of amiodarone, where timely diagnosis is crucial to minimize unnecessary testing, avoid harmful treatments, and prevent life-threatening hemorrhagic complications.
Case Report (n=1)
Amiodarone can cause a rare, delayed-onset, immune-mediated severe thrombocytopenia that requires prompt recognition and drug discontinuation to prevent hemorrhagic complications.
Answers are grounded in this paper and cite their sources.
Amiodarone-induced thrombocytopenia warrants consideration in unexplained cytopenias; this case leaves open incidence, timing, and management.
Thrombocytopenia is a rare immune-mediated hematologic complication of amiodarone. We describe a case of delayed-onset amiodarone-induced thrombocytopenia in a 72-year-old male and highlight the process of working it up. A timely diagnosis of drug-induced immune thrombocytopenia is crucial in order to minimize unnecessary testing, avoid treatments with potential harm, and prevent life-threatening hemorrhagic complications.
No takes yet. Share an insight, caveat, or question.
Chhatrala et al. (2021) conducted a case report in Amiodarone-induced immune thrombocytopenia (n=1). Amiodarone was evaluated on Platelet count nadir. Amiodarone exposure in a 72-year-old male resulted in severe immune thrombocytopenia with a platelet nadir of 14 K/mm3, which began recovering after drug discontinuation.
Synapse has enriched 10 related papers. Consider them for comparative context: